{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:59Z","timestamp":1793502779936,"version":"4.5.0"},"reference-count":199,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaci.2025.01.017","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:10:45Z","timestamp":1737547845000},"page":"1133-1148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Targeting alarmins in asthma: From bench to clinic"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-1470","authenticated-orcid":false,"given":"Ayobami","family":"Akenroye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.01.017_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41467-018-03886-6","article-title":"The IL-33\u2013PIN1\u2013IRAK-M axis is critical for type 2 immunity in IL-33\u2013induced allergic airway inflammation","volume":"9","author":"Nechama","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.01.017_bib2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ni.3489","article-title":"Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis","volume":"17","author":"Klose","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.coi.2005.06.002","article-title":"Alarmins: chemotactic activators of immune responses","volume":"17","author":"Oppenheim","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071105","article-title":"The role of airway epithelial cell alarmins in asthma","volume":"11","author":"Whetstone","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2025.01.017_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.all.0000200503.77295.bb","article-title":"The role of Toll-like receptors and related receptors of the innate immune system in asthma","volume":"6","author":"Yang","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJM200008033430506","article-title":"Innate immunity","volume":"343","author":"Medzhitov","year":"2000","journal-title":"N Engl J Med"},{"issue":"6640","key":"10.1016\/j.jaci.2025.01.017_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila Toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.01.017_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2011.06.041","article-title":"Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4\u2013dependent thymic stromal lymphopoietin\/OX40 ligand\/OX40 signaling pathways","volume":"128","author":"Li","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12577","article-title":"Alarmins and immunity","volume":"280","author":"Yang","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.01.017_bib10","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41590-019-0524-9","article-title":"TSLP: from allergy to cancer","volume":"20","author":"Corren","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091108","article-title":"Monoclonal antibodies targeting alarmins: a new perspective for biological therapies of severe asthma","volume":"9","author":"Pelaia","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaci.2025.01.017_bib13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcmgh.2017.01.005","article-title":"Thymic stromal lymphopoietin: to cut a long story short","volume":"3","author":"Tsilingiri","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2025.01.017_bib14","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fimmu.2018.01595","article-title":"Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2009.05128.x","article-title":"Thymic stromal lymphopoietin","volume":"1183","author":"He","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaci.2025.01.017_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaci.2012.07.031","article-title":"Thymic stromal lymphopoietin is induced by respiratory syncytial virus\u2013infected airway epithelial cells and promotes a type 2 response to infection","volume":"130","author":"Lee","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2193","article-title":"Rhinovirus and asthma: challenges and opportunities","volume":"31","author":"Ortega","year":"2021","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jaci.2025.01.017_bib18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.4049\/jimmunol.179.2.1080","article-title":"TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells","volume":"179","author":"Kato","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2222.2008.03151.x","article-title":"Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions","volume":"39","author":"Tanaka","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2332\/allergolint.11-RAI-0395","article-title":"TSLP expression: cellular sources, triggers, and regulatory mechanisms","volume":"61","author":"Takai","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2025.01.017_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nsmb.2794","article-title":"Structural basis of the proinflammatory signaling complex mediated by TSLP","volume":"21","author":"Verstraete","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jaci.2025.01.017_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14937","article-title":"Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma","volume":"8","author":"Verstraete","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.01.017_bib24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3389\/fimmu.2020.01557","article-title":"Modulation of signaling mediated by TSLP and IL-7\u00a0in\u00a0inflammation, autoimmune diseases, and cancer","volume":"11","author":"Markovi\u0107","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/76923","article-title":"Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin","volume":"1","author":"Pandey","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1084\/jem.20051745","article-title":"Thymic stromal lymphopoietin: master switch for allergic inflammation","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/ni1247","article-title":"Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice","volume":"6","author":"Zhou","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/bloodadvances.2016002352","article-title":"IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells","volume":"1","author":"Camelo","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2025.01.017_bib29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ni.1894","article-title":"Programming dendritic cells to induce TH2 and tolerogenic responses","volume":"11","author":"Pulendran","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib30","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.immuni.2006.03.019","article-title":"Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin\u2013activated dendritic cells","volume":"24","author":"Wang","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.01.017_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2012.08.015","article-title":"The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells","volume":"37","author":"Mj\u00f6sberg","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.01.017_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.alit.2020.01.001","article-title":"Anti-TSLP antibodies: targeting a master regulator of type 2 immune responses","volume":"69","author":"Nakajima","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2025.01.017_bib33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaci.2025.01.017_bib34","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20051135","article-title":"TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand","volume":"202","author":"Ito","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1378\/chest.11-1730","article-title":"OX40\/OX40 ligand interactions in T-cell regulation and asthma","volume":"141","author":"Kaur","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2025.01.017_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","article-title":"The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses","volume":"20","author":"Carreno","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1710-1492-6-4","article-title":"TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic immunity in asthmatic airway","volume":"6","author":"Nguyen","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib38","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3109\/02770903.2015.1026441","article-title":"Correlation of TSLP, IL-33, and CD4+CD25+FOXP3+ T regulatory (Treg) in pediatric asthma","volume":"52","author":"Chauhan","year":"2015","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2025.01.017_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2009-0168OC","article-title":"Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation","volume":"43","author":"Wong","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2025.01.017_bib40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1398-9995.2012.02868.x","article-title":"Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps","volume":"67","author":"Morshed","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib41","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","article-title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity","volume":"174","author":"Ying","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib42","doi-asserted-by":"crossref","first-page":"7134","DOI":"10.4049\/jimmunol.0902515","article-title":"Thymic stromal lymphopoietin receptor\u2013mediated IL-6 and CC\/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1\/2, p38, and JNK) and STAT3 pathways","volume":"184","author":"Shan","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib43","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2014.12.1918","article-title":"Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma","volume":"135","author":"Smith","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib44","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/ijbs.4874","article-title":"Role of IL-6 in asthma and other inflammatory pulmonary diseases","volume":"8","author":"Rincon","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jaci.2025.01.017_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/01902148.2018.1536175","article-title":"TSLP promotes asthmatic airway remodeling via p38-STAT3 signaling pathway in human lung fibroblast","volume":"44","author":"Cao","year":"2018","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.jaci.2025.01.017_bib46","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.imbio.2017.05.010","article-title":"Thymic stromal lymphopoietin and apocynin alter the expression of airway remodeling factors in human rhinovirus\u2013infected cells","volume":"222","author":"Wieczfinska","year":"2017","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaci.2025.01.017_bib47","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1476-5381.2009.00374.x","article-title":"Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives","volume":"158","author":"Maarsingh","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2025.01.017_bib48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaci.2024.03.023","article-title":"Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma","volume":"154","author":"Tang","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.01.017_bib50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-065X.2011.01029.x","article-title":"The genetics of asthma and allergic disease: a 21st century perspective","volume":"242","author":"Ober","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.01.017_bib51","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ng.888","article-title":"Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations","volume":"43","author":"Torgerson","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2025.01.017_bib52","first-page":"362","article-title":"Association between two single nucleotide polymorphisms of thymic stromal lymphopoietin (TSLP) gene and asthma in Iranian population","volume":"19","author":"Ranjbar","year":"2020","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"6 suppl","key":"10.1016\/j.jaci.2025.01.017_bib53","first-page":"2729","article-title":"Thymic stromal lymphopoietin (TSLP) gene variant rs1837253 is significantly associated with asthma prevalence in Pakistani Pashtun women","volume":"33","author":"Afzal","year":"2020","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.jaci.2025.01.017_bib54","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1398-9995.2010.02415.x","article-title":"TSLP polymorphisms are associated with asthma in a sex-specific fashion","volume":"65","author":"Hunninghake","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib55","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.4049\/jimmunol.181.9.6557","article-title":"Reversal of thymic stromal lymphopoietin\u2013induced airway inflammation through inhibition of Th2 responses","volume":"181","author":"Zhou","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib56","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2020.03.032","article-title":"TSLP drives acute TH2-cell differentiation in lungs","volume":"146","author":"Lai","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1084\/jem.20050199","article-title":"A role for TSLP in the development of inflammation in an asthma model","volume":"202","author":"Al-Shami","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib58","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/ncomms3675","article-title":"Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation","volume":"4","author":"Kabata","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.01.017_bib59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaci.2017.03.032","article-title":"Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin","volume":"141","author":"Liu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-020-01503-z","article-title":"SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma","volume":"21","author":"Wechsler","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2025.01.017_bib61","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib62","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2023.11.915","article-title":"Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation","volume":"153","author":"Andreasson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/thorax-2022-219192","article-title":"Plasma thymic stromal lymphopoietin (TSLP) in adults with non-severe asthma: the EGEA study","volume":"78","author":"Ibrahim","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2025.01.017_bib64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.imlet.2016.08.004","article-title":"Increased expression of thymic stromal lymphopoietin in induced sputum from asthmatic children","volume":"178","author":"Berra\u00efes","year":"2016","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaci.2025.01.017_bib65","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.4049\/jimmunol.1701455","article-title":"Elevated expression of IL-33 and TSLP in the airways of human asthmatics in\u00a0vivo: a potential biomarker of severe refractory disease","volume":"200","author":"Li","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000444017","article-title":"Increased levels of interleukin-33 and thymic stromal lymphopoietin in exhaled breath condensate in chronic bronchial asthma","volume":"169","author":"Gl\u00fcck","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.971073","article-title":"TSLP bronchoalveolar lavage levels at baseline are linked to clinical disease severity and reduced lung function in children with asthma","volume":"10","author":"Chorvinsky","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2025.01.017_bib68","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1038\/s41598-021-86179-1","article-title":"Blood tryptase and thymic stromal lymphopoietin levels predict the risk of exacerbation in severe asthma","volume":"11","author":"Ko","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2025.01.017_bib69","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib71","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","author":"Nopsopon","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01193-2022","article-title":"Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma","volume":"61","author":"Gauvreau","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2025.01.017_bib73","article-title":"Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma","author":"Sverrild","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib74","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib75","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.01.017_bib76","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib77","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0002-9440(10)63631-0","article-title":"Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules","volume":"163","author":"Baekkevold","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2025.01.017_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-immunol-101320-124243","article-title":"Emerging functions of IL-33 in homeostasis and immunity","volume":"40","author":"Dwyer","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1\u2013like cytokine that signals via the IL-1 receptor\u2013related protein ST2 and induces T helper type 2\u2013associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.01.017_bib81","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI124606","article-title":"Epithelial cell\u2013derived cytokines: more than just signaling the alarm","volume":"129","author":"Roan","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.01.017_bib82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","article-title":"IL-1, IL-18, and IL-33 families of cytokines","volume":"223","author":"Arend","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.01.017_bib83","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jaci.2008.04.005","article-title":"A novel IL-1 family cytokine, IL-33, potently activates human eosinophils","volume":"121","author":"Cherry","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in\u00a0vivo: a novel \u201calarmin\u201d","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.01.017_bib85","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3389\/fimmu.2018.02601","article-title":"The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity","volume":"9","author":"Afferni","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib86","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: the new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"suppl\u00a02","key":"10.1016\/j.jaci.2025.01.017_bib87","doi-asserted-by":"crossref","first-page":"i101","DOI":"10.1136\/annrheumdis-2011-200589","article-title":"IL-33: a Janus cytokine","volume":"71","author":"Liew","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2025.01.017_bib88","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaci.2016.01.032","article-title":"Platelets constitutively express IL-33 protein and modulate eosinophilic airway inflammation","volume":"138","author":"Takeda","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib89","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1074\/jbc.M116.769422","article-title":"Endogenous prostaglandin E2 amplifies IL-33 production by macrophages through an E prostanoid (EP)2\/EP4-cAMP-EPAC\u2013dependent pathway","volume":"292","author":"Samuchiwal","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2025.01.017_bib90","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.01.017_bib91","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12004","article-title":"Interleukin-33 in allergy","volume":"67","author":"Ohno","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib92","doi-asserted-by":"crossref","first-page":"18660","DOI":"10.1073\/pnas.0705939104","article-title":"IL-1 receptor accessory protein is essential for IL-33\u2013induced activation of T lymphocytes and mast cells","volume":"104","author":"Ali","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.01.017_bib93","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.4049\/jimmunol.179.4.2551","article-title":"IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex","volume":"179","author":"Chackerian","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107847","article-title":"The central role of IL-33\/IL-1RL1 pathway in asthma: from pathogenesis to intervention","volume":"225","author":"Saikumar Jayalatha","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaci.2025.01.017_bib95","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-030-38315-2_7","article-title":"ST2 signaling in the tumor microenvironment","volume":"1240","author":"Chang","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaci.2025.01.017_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155891","article-title":"Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine","volume":"156","author":"Cayrol","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2025.01.017_bib97","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jaci.2019.02.028","article-title":"IL-33trap is a novel IL-33\u2013neutralizing biologic that inhibits allergic airway inflammation","volume":"144","author":"Holgado","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s12079-018-0464-4","article-title":"A network map of IL-33 signaling pathway","volume":"12","author":"Pinto","year":"2018","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.jaci.2025.01.017_bib99","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.it.2016.03.007","article-title":"IL-33 in T cell differentiation, function, and immune homeostasis","volume":"37","author":"Peine","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.immuni.2014.06.006","article-title":"GATA-3 function in innate and adaptive immunity","volume":"41","author":"Tindemans","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.01.017_bib101","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.coi.2010.10.006","article-title":"IL-33 family members and asthma\u2014bridging innate and adaptive immune responses","volume":"22","author":"Lloyd","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib102","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jaci.2021.02.019","article-title":"Optimal human pathogenic TH2 cell effector function requires local epithelial cytokine signaling","volume":"148","author":"Calise","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib103","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jaci.2017.01.015","article-title":"IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs","volume":"140","author":"Chen","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib104","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3389\/fimmu.2019.00692","article-title":"IL-33 mediated inflammation in chronic respiratory diseases\u2014understanding the role of the member of IL-1 superfamily","volume":"10","author":"Gabryelska","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib105","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fimmu.2019.00364","article-title":"IL33: roles in allergic inflammation and therapeutic perspectives","volume":"10","author":"Chan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib106","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefran\u00e7ais","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.01.017_bib107","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.4049\/jimmunol.1601223","article-title":"Highly selective cleavage of cytokines and chemokines by the human mast cell chymase and neutrophil cathepsin G","volume":"198","author":"Fu","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib108","doi-asserted-by":"crossref","first-page":"10281","DOI":"10.1073\/pnas.1404182111","article-title":"IL-33\/ST2 axis promotes mast cell survival via BCLXL","volume":"111","author":"Wang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.01.017_bib109","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1038\/s41467-018-07387-4","article-title":"Integrin CD11b activation drives anti-tumor innate immunity","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.01.017_bib110","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/labinvest.2008.82","article-title":"Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils","volume":"88","author":"Suzukawa","year":"2008","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaci.2025.01.017_bib111","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3109\/02770903.2014.921196","article-title":"IL-33 promotes airway remodeling and is a marker of asthma disease severity","volume":"51","author":"Guo","year":"2014","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2025.01.017_bib112","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imm.12589","article-title":"Nasal administration of interleukin-33 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma surrogate","volume":"148","author":"Shan","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2025.01.017_bib114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.immuni.2018.04.023","article-title":"Amphiregulin-producing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis","volume":"49","author":"Morimoto","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.01.017_bib115","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1038\/s41467-020-18466-w","article-title":"IL-33\u2013ST2 axis regulates myeloid cell differentiation and activation enabling effective club cell regeneration","volume":"11","author":"Dagher","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.01.017_bib116","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/ng.323","article-title":"Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction","volume":"41","author":"Gudbjartsson","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2025.01.017_bib117","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa0906312","article-title":"A large-scale, consortium-based genomewide association study of asthma","volume":"363","author":"Moffatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib118","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87871","article-title":"IL1RL1 asthma risk variants regulate airway type 2 inflammation","volume":"1","author":"Gordon","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.01.017_bib119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1465-9921-4-14","article-title":"Association studies for asthma and atopic diseases: a comprehensive review of the literature","volume":"4","author":"Hoffjan","year":"2003","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2025.01.017_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006659","article-title":"A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma","volume":"13","author":"Smith","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jaci.2025.01.017_bib121","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2020.04.051","article-title":"Phenotypic and functional translation of IL33 genetics in asthma","volume":"147","author":"Ketelaar","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib122","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00408-019-00301-9","article-title":"The impact of interleukin (IL)-33 gene polymorphisms and environmental factors on risk of asthma in the Iranian population","volume":"198","author":"Matloubi","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jaci.2025.01.017_bib123","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/ng.2694","article-title":"Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization","volume":"45","author":"B\u00f8nnelykke","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2025.01.017_bib124","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ejhg.2010.191","article-title":"Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia","volume":"19","author":"Ferreira","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jaci.2025.01.017_bib125","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thoraxjnl-2011-201262","article-title":"Genome-wide association study to identify genetic determinants of severe asthma","volume":"67","author":"Wan","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2025.01.017_bib126","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132446","article-title":"Phenotypic and functional translation of IL1RL1 locus polymorphisms in lung tissue and asthmatic airway epithelium","volume":"5","author":"Portelli","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.01.017_bib127","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jaci.2013.12.1080","article-title":"Association of IL33\u2013IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood","volume":"134","author":"Savenije","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib128","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2014.02.002","article-title":"Alternaria-derived serine protease activity drives IL-33\u2013mediated asthma exacerbations","volume":"134","author":"Snelgrove","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.01.016","article-title":"Lung-resident CD69+ST2+ TH2 cells mediate long-term type 2 memory to inhaled antigen in mice","author":"Kobayashi","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm.3883","article-title":"The emerging role of resident memory T cells in protective immunity and inflammatory disease","volume":"21","author":"Park","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib131","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4049\/jimmunol.1302984","article-title":"IL-33 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure","volume":"193","author":"Iijima","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib132","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201406-1039OC","article-title":"IL-33\u2013dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in\u00a0vivo","volume":"190","author":"Jackson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib133","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.1800709","article-title":"Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa","volume":"201","author":"Wang","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib134","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1164\/rccm.201712-2468LE","article-title":"Expression of IL-33 and TSLP and their receptors in asthmatic airways after inhaled allergen challenge","volume":"198","author":"Al-Sajee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/ijpvm.IJPVM_179_16","article-title":"Comparison of interleukin-33 serum levels in asthmatic patients with a control\u00a0group and relation with the severity of the disease","volume":"8","author":"Momen","year":"2017","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib136","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-018-0872-2","article-title":"Serum sST2 levels predict severe exacerbation of asthma","volume":"19","author":"Watanabe","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2025.01.017_bib137","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.immuni.2024.05.003","article-title":"Mast cells control lung type 2 inflammation via prostaglandin E2-driven soluble ST2","volume":"57","author":"Alhallak","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.01.017_bib138","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cts.13157","article-title":"Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: phase I first-in-human and first-in-patient trials","volume":"15","author":"Kosloski","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaci.2025.01.017_bib139","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib140","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib141","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1111\/bcp.14361","article-title":"The first-in-human study of CNTO 7160, an anti\u2013interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis","volume":"86","author":"Nnane","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2025.01.017_bib142","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281205","article-title":"Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: a phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial","volume":"18","author":"Akinseye","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.01.017_bib143","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u201cbomb\u201d (blood eosinophils) meets \u201cmagnet\u201d (FeNO) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"key":"10.1016\/j.jaci.2025.01.017_bib144","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1172\/JCI65570","article-title":"Long-term IL-33\u2013producing epithelial progenitor cells in chronic obstructive lung disease","volume":"123","author":"Byers","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.01.017_bib145","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1165\/rcmb.2018-0402OC","article-title":"Cigarette smoke triggers IL-33\u2013associated inflammation in a model of late-stage chronic\u00a0obstructive pulmonary disease","volume":"61","author":"Lee","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2025.01.017_bib146","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib147","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib148","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib149","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41423-020-0412-0","article-title":"Neutrophil chemoattractant receptors in health and disease: double-edged swords","volume":"17","author":"Metzemaekers","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib151","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib152","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.jaci.2016.03.056","article-title":"IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells","volume":"138","author":"Galand","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib153","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.immuni.2019.03.023","article-title":"Mechanical skin injury promotes food anaphylaxis by driving intestinal mast cell expansion","volume":"50","author":"Leyva-Castillo","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.01.017_bib154","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaci.2012.08.002","article-title":"IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization","volume":"131","author":"Chu","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti\u2013IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.01.017_bib156","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imr.12558","article-title":"IL-25 in allergic inflammation","volume":"278","author":"Xu","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.01.017_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691559","article-title":"Roles of IL-25 in type 2 inflammation and autoimmune pathogenesis","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib158","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaci.2020.12.628","article-title":"IL-25 (IL-17E) in epithelial immunology and pathophysiology","volume":"148","author":"Borowczyk","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"7585","key":"10.1016\/j.jaci.2025.01.017_bib159","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature16161","article-title":"Tuft-cell\u2013derived IL-25 regulates an intestinal ILC2-epithelial response circuit","volume":"529","author":"von Moltke","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.01.017_bib160","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj0474","article-title":"Tuft cell\u2013produced cysteinyl leukotrienes and IL-25 synergistically initiate lung type 2 inflammation","volume":"6","author":"Ualiyeva","year":"2021","journal-title":"Sci Immunol"},{"issue":"6279","key":"10.1016\/j.jaci.2025.01.017_bib161","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1126\/science.aaf1648","article-title":"Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut","volume":"351","author":"Howitt","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jaci.2025.01.017_bib162","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1165\/rcmb.2012-0304OC","article-title":"Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells","volume":"49","author":"Kouzaki","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2025.01.017_bib163","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nri2275","article-title":"Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma","volume":"8","author":"Hammad","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib164","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.20070406","article-title":"IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC\u2013activated Th2 memory cells","volume":"204","author":"Wang","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib165","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3389\/fimmu.2019.01293","article-title":"TRAF Regulation of IL-17 cytokine signaling","volume":"10","author":"Swaidani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib166","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12967-016-0808-x","article-title":"Increased expression of upstream TH2-cytokines in a mouse model of viral-induced asthma exacerbation","volume":"14","author":"Mahmutovic Persson","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib167","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.865973","article-title":"Innate immune responses by respiratory viruses, including rhinovirus, during asthma exacerbation","volume":"13","author":"Nakagome","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib168","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib169","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1398-9995.2006.01102.x","article-title":"IL-25 regulates the expression of adhesion molecules on eosinophils: mechanism of eosinophilia in allergic inflammation","volume":"61","author":"Cheung","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib170","first-page":"222","article-title":"Adhesion to fibronectin primes eosinophils via alpha 4 beta 1 (VLA-4)","volume":"82","author":"Anwar","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2025.01.017_bib171","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00260-2020","article-title":"Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics","volume":"56","author":"Porsbjerg","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2025.01.017_bib172","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201403-0505OC","article-title":"Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma","volume":"190","author":"Cheng","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib173","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/thoraxjnl-2012-202003","article-title":"IL-25 drives remodelling in allergic airways disease induced by house dust mite","volume":"68","author":"Gregory","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2025.01.017_bib174","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/resp.12707","article-title":"Interleukin (IL)-25: pleiotropic roles in asthma","volume":"21","author":"Yao","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.jaci.2025.01.017_bib175","article-title":"Neutrophils and asthma","volume":"12","author":"Yamasaki","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jaci.2025.01.017_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034698","article-title":"RAGE expression in human T cells: a link between environmental factors and adaptive immune responses","volume":"7","author":"Akirav","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.01.017_bib177","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib178","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/917108","article-title":"The receptor for advanced glycation end products (RAGE) and the lung","volume":"2010","author":"Buckley","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.jaci.2025.01.017_bib179","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaci.2019.03.019","article-title":"The\u00a0receptor for advanced glycation end products is a critical mediator of type\u00a02 cytokine signaling in the lungs","volume":"144","author":"Perkins","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib180","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/all.14563","article-title":"RAGE and TLR4 differentially regulate airway hyperresponsiveness: implications for COPD","volume":"76","author":"Allam","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib181","article-title":"sRAGE alleviates neutrophilic asthma by blocking HMGB1\/RAGE signalling in airway dendritic cells","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2025.01.017_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259026","article-title":"Role of the IL-33\/ST2 axis in cardiovascular disease: a systematic review and meta-analysis","volume":"16","author":"Sun","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.01.017_bib183","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaci.2025.01.017_bib184","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","article-title":"Identification of serum soluble ST2 receptor as a novel heart failure biomarker","volume":"107","author":"Weinberg","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2025.01.017_bib185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000391","article-title":"Thymic stromal lymphopoietin attenuates the development of atherosclerosis in ApoE\u2212\/\u2212 mice","volume":"2","author":"Yu","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"337","key":"10.1016\/j.jaci.2025.01.017_bib186","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1938","article-title":"Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine\u2013driven inflammation and fibrosis","volume":"8","author":"Vannella","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib187","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cea.12235","article-title":"OX40L blockade and allergen-induced airway responses in subjects with mild asthma","volume":"44","author":"Gauvreau","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib188","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10372","key":"10.1016\/j.jaci.2025.01.017_bib189","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.01.017_bib190","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib191","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/mi.2015.21","article-title":"The prostaglandin D2 receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung","volume":"8","author":"Wojno","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib192","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3904\/kjim.2018.248","article-title":"Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma","volume":"35","author":"Lee","year":"2020","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib193","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2025.01.017_bib194","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib195","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.01.017_bib196","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/cea.12357","article-title":"Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics","volume":"44","author":"Diamant","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib197","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13223-017-0183-z","article-title":"Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies","volume":"13","author":"Ratner","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib198","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2017.11.043","article-title":"Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in\u00a0vivo","volume":"142","author":"Toki","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.01.017_bib199","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1111\/all.14879","article-title":"Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice","volume":"76","author":"Toki","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.01.017_bib200","article-title":"Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs","author":"Hayashi","year":"2024153793","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:02:48Z","timestamp":1744012968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":199,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0091674925000685"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.01.017","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting alarmins in asthma: From bench to clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}